Expert review of gastroenterology & hepatology · 2026
Adjuvant therapy in biliary tract tumors: how will immunotherapy fit in the future?
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
González-Sánchez Alejandro, Rosero Diana, Fuentes Raquel, Ruiz Hispán Eva, Lamarca Angela
Аннотация
INTRODUCTION: Biliary tract tumors comprise a group of poor prognosis malignancies, most of them being diagnosed at an advanced stage. Standard treatments include surgery with curative intent and adjuvant chemotherapy. Even so, the benefit obtained is marginal, and relapses are frequent.
AREAS COVERED: Here, we made a review of the literature trying to summarize all trials related to adjuvant therapy, as well as those yet to come. We also focused on detecting the unmet needs in this field, which may represent a change in the current strategy.
EXPERT OPINION: A clear definition of resectability, risk stratification, intensification of treatment with immunotherapy, and targeted therapies, as well as moving treatment from an adjuvant to a perioperative scenario are, in our view, factors that could increase the rate of cure in this scenario.
AREAS COVERED: Here, we made a review of the literature trying to summarize all trials related to adjuvant therapy, as well as those yet to come. We also focused on detecting the unmet needs in this field, which may represent a change in the current strategy.
EXPERT OPINION: A clear definition of resectability, risk stratification, intensification of treatment with immunotherapy, and targeted therapies, as well as moving treatment from an adjuvant to a perioperative scenario are, in our view, factors that could increase the rate of cure in this scenario.